Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 67.95 percent increase over losses of $(0.78) per
The Green Market Report Cannabis Company Index has selected the six companies it plans to add for the third quarter while removing six others after the second quarter, which turned out to be "rough for cannabis stocks."
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months.
Needham analyst Serge Belanger highlighted companies in the firm's coverage universe that have key catalysts in the third quarter.
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains relatively small.